Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bio_kruncher	12/2/2004 2:28:02 PM
	of 52153

more on mucositis Curagen anounces fastrack for its mucositis drug. The company PR is good but a Reuters press release makes mistake of confusing priority review with fast track. This confusion seems to happen often, even to people working in the industry. UPDATE 1-Curagen gets fast track for oral mucositis drug Thu Dec 2, 2004 10:34 AM ET (Updates with details, stock price) NEW YORK, Dec 2 (Reuters) - Curagen Corp. (CRGN.O: Quote, Profile, Research) said on Thursday that U.S. regulators agreed to an accelerated review of its experimental treatment for mouth sores resulting from radiation or chemotherapy. Curagen's shares rose 13 percent to $7.55 in early trading on Nasdaq. The U.S. Food and Drug Administration granted the drug, which has the working title CG53135 "fast track" status, which means the agency could reach a decision on whether to approve it within six months, rather than the normal 12-month period.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next